- Home
- TRAX vs CBIO Comparison
TRAX vs CBIO Comparison
Compare TRAX & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRAX | CBIO |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.9M | 537.5M |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TRAX | CBIO |
|---|---|---|
| Price | $36.40 | $14.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | ★ 561.3K | 390.5K |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,500.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $279.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.69 | $8.72 |
| 52 Week High | $49.91 | $27.41 |
Technical Indicators
Market Signals| Indicator | TRAX | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 35.19 |
| Support Level | $15.69 | $9.95 |
| Resistance Level | $48.94 | $18.53 |
| Average True Range (ATR) | 2.80 | 1.45 |
| MACD | -0.46 | -0.52 |
| Stochastic Oscillator | 17.15 | 13.36 |
Price Performance
Historical ComparisonAbout CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.